NEW YORK (GenomeWeb News) – Ariosa Diagnostics has filed a regulatory document with the US Securities and Exchange Commission for an initial public offering.

In its preliminary prospectus filed with the SEC on Monday, the San Jose, Calif.-based developer of non-invasive prenatal tests said it intends to offer $69 million in a proposed maximum aggregate offering price. It has not priced its shares yet or said how many share it plans to offer.

Ariosa said that it plans to list its shares on the Nasdaq Global Market under ticker symbol "AROS."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.